Compared to small drug molecules (EGFR-TKIs) and monoclonal antibodies (PD-1/PD-L1 checkpoint inhibitors), the two most important types of drug molecules in NSCLC therapy, siRNA has several distinct advantages. Here, CD274 is linked to non-small cell lung carcinoma.